• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.

作者信息

Newell Kelly A

机构信息

Faculty of Science, Medicine & Health and Illawarra Health & Medical Research Institute, University of Wollongong, Northfields Avenue Wollongong, NSW, 2522 Australia.

出版信息

Future Med Chem. 2013 Sep;5(13):1471-4. doi: 10.4155/fmc.13.137.

DOI:10.4155/fmc.13.137
PMID:24024939
Abstract
摘要

相似文献

1
Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.精神分裂症中的代谢型谷氨酸受体5：抗精神病药物研发的新证据
Future Med Chem. 2013 Sep;5(13):1471-4. doi: 10.4155/fmc.13.137.
2
Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012).用于治疗精神分裂症的代谢型谷氨酸受体5阳性变构调节剂（2004 - 2012年）
Pharm Pat Anal. 2013 Jan;2(1):93-108. doi: 10.4155/ppa.12.82.
3
Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?不断演变的时代背景下精神分裂症药物的研发：新的药物靶点是否达到预期？
J Psychopharmacol. 2015 Feb;29(2):230-8. doi: 10.1177/0269881114565806. Epub 2015 Jan 13.
4
Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.代谢型谷氨酸受体5及其转运分子Norbin和Tamalin在精神分裂症患者海马CA1区中表达增加。
Schizophr Res. 2015 Aug;166(1-3):212-8. doi: 10.1016/j.schres.2015.05.001. Epub 2015 Jun 2.
5
Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.神经激肽 3 调节剂治疗精神分裂症的研究进展：分子开发和临床进展。
Future Med Chem. 2013 Sep;5(13):1525-46. doi: 10.4155/fmc.13.122.
6
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.精神分裂症的药物治疗：当前和未来治疗药物的药理学和临床效应的批判性评价。
Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15.
7
Metabotropic glutamate receptor 5 neuroimaging in schizophrenia.精神分裂症中代谢型谷氨酸受体5的神经影像学研究
Schizophr Res. 2017 May;183:95-101. doi: 10.1016/j.schres.2016.11.008. Epub 2016 Nov 12.
8
[Discovery of novel antipsychotics targeting group II metabotropic glutamate receptor].[靶向Ⅱ型代谢型谷氨酸受体的新型抗精神病药物的发现]
Nihon Yakurigaku Zasshi. 2012 Sep;140(3):111-5. doi: 10.1254/fpj.140.111.
9
[Targeting metabotropic glutamate receptors to develop novel antipsychotics].[靶向代谢型谷氨酸受体开发新型抗精神病药物]
Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):207-13.
10
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.后基因组时代抗精神病药物发现的新机遇
J Med Chem. 2008 Mar 13;51(5):1077-107. doi: 10.1021/jm701094q. Epub 2008 Jan 17.

引用本文的文献

1
Rare Pathogenic Variants in Genes Implicated in Glutamatergic Neurotransmission Pathway Segregate with Schizophrenia in Pakistani Families.巴基斯坦家族中谷氨酸能神经传递途径相关基因的罕见致病性变异与精神分裂症分离。
Genes (Basel). 2021 Nov 26;12(12):1899. doi: 10.3390/genes12121899.
2
mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia.代谢型谷氨酸受体 5 受体的可利用性与慢性精神分裂症男性患者较低水平的阴性症状和较好的认知功能有关。
Hum Brain Mapp. 2020 Jul;41(10):2762-2781. doi: 10.1002/hbm.24976. Epub 2020 Mar 9.
3
Development of 1-Pyrazolo[3,4-]pyridines as Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators.
1-吡唑并[3,4-]吡啶作为代谢型谷氨酸受体5正向变构调节剂的研发
ACS Med Chem Lett. 2016 Oct 3;7(12):1082-1086. doi: 10.1021/acsmedchemlett.6b00292. eCollection 2016 Dec 8.
4
Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.代谢型谷氨酸受体mGluR2/3和mGluR5在精神病性和非精神病性抑郁症、双相情感障碍及精神分裂症患者前扣带回皮质中的结合：对基于新型代谢型谷氨酸受体的治疗方法的启示
J Psychiatry Neurosci. 2014 Nov;39(6):407-16. doi: 10.1503/jpn.130242.
5
Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics.重新审视精神疾病中代谢型谷氨酸受体5的病理发现：对新型疗法未来的启示
BMC Psychiatry. 2014 Jan 28;14:23. doi: 10.1186/1471-244X-14-23.